Yuzuru Hosoda1,2, Norihiko Hino2, Toru Motokura1. 1. Division of Clinical Laboratory Medicine, Department of Pathophysiological and Therapeutic Science, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8503, Japan. 2. †Department of Hematology, Tottori University Hospital, Yonago 683-8504, Japan.
Abstract
BACKGROUND: Several prognostic indices for diffuse large B-cell lymphoma (DLBCL) have been developed. Which index is appropriate for Japanese patients with DLBCL treated in real-world practice is unknown. METHODS: The prognostic performances of the original international prognostic index (IPI), age-adjusted IPI, National Comprehensive Cancer Network-IPI, elderly IPI and revised IPI were compared using patients with DLBCL treated in a single institute in the Yonago area in Japan. RESULTS: From 2005 through 2015, 182 patients with de novo DLBCL were treated with chemotherapy in Tottori University Hospital; 154 (85%) patients received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) although full dose was administered in 63 (35%) patients. The median age of the patients was 71 years (range 18 to 91). Three-year overall survival rate was 71.8% (95% CI, 64.1% to 78.2%). All indices significantly discriminate risk groups for overall survival of the patients (P < 0.001). Although no statistical difference of performance was found among these indices, the best scores of model fit/discrimination measures were beaten out by age-adjusted IPI, the simplest and three-factor model. CONCLUSION: Age-adjusted IPI is still usable in real-world practice while a better predictive model is desired for Japanese patients with DLBCL.
BACKGROUND: Several prognostic indices for diffuse large B-cell lymphoma (DLBCL) have been developed. Which index is appropriate for Japanese patients with DLBCL treated in real-world practice is unknown. METHODS: The prognostic performances of the original international prognostic index (IPI), age-adjusted IPI, National Comprehensive Cancer Network-IPI, elderly IPI and revised IPI were compared using patients with DLBCL treated in a single institute in the Yonago area in Japan. RESULTS: From 2005 through 2015, 182 patients with de novo DLBCL were treated with chemotherapy in Tottori University Hospital; 154 (85%) patients received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) although full dose was administered in 63 (35%) patients. The median age of the patients was 71 years (range 18 to 91). Three-year overall survival rate was 71.8% (95% CI, 64.1% to 78.2%). All indices significantly discriminate risk groups for overall survival of the patients (P < 0.001). Although no statistical difference of performance was found among these indices, the best scores of model fit/discrimination measures were beaten out by age-adjusted IPI, the simplest and three-factor model. CONCLUSION: Age-adjusted IPI is still usable in real-world practice while a better predictive model is desired for Japanese patients with DLBCL.
Entities:
Keywords:
Japan; aged; lymphoma, large B-cell, diffuse; prognosis; rituximab
Authors: Ranjana H Advani; Haiyan Chen; Thomas M Habermann; Vicki A Morrison; Edie A Weller; Richard I Fisher; Bruce A Peterson; Randy D Gascoyne; Sandra J Horning Journal: Br J Haematol Date: 2010-10 Impact factor: 6.998
Authors: Thomas Melchardt; Katharina Troppan; Lukas Weiss; Clemens Hufnagl; Daniel Neureiter; Wolfgang Tränkenschuh; Georg Hopfinger; Teresa Magnes; Alexander Deutsch; Peter Neumeister; Hubert Hackl; Richard Greil; Martin Pichler; Alexander Egle Journal: Br J Haematol Date: 2014-09-19 Impact factor: 6.998
Authors: Christian Gisselbrecht; Bertram Glass; Nicolas Mounier; Devinder Singh Gill; David C Linch; Marek Trneny; Andre Bosly; Nicolas Ketterer; Ofer Shpilberg; Hans Hagberg; David Ma; Josette Brière; Craig H Moskowitz; Norbert Schmitz Journal: J Clin Oncol Date: 2010-07-26 Impact factor: 44.544
Authors: Patrick G Morris; Denise D Correa; Joachim Yahalom; Jeffrey J Raizer; David Schiff; Barbara Grant; Sean Grimm; Rose K Lai; Anne S Reiner; Kathy Panageas; Sasan Karimi; Richard Curry; Gaurav Shah; Lauren E Abrey; Lisa M DeAngelis; Antonio Omuro Journal: J Clin Oncol Date: 2013-10-07 Impact factor: 44.544